GENITOURINARY CANCERS

Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor erdafitinib directly into the bladder, marking the first mutation-directed therapy for non-muscle invasive bladder cancer that offers patients an oncologically beneficial and bladder-sparing option with minimal toxicity.

A discussion with the patient about the importance of bone health when treated with androgen-deprivation therapy (ADT) should occur early in the treatment plan.

The use of PSMA PET scans are useful in initial staging, detecting biochemical relapse, and eligibility for radionuclide treatment.

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.

Althopugh current prostate cancer biomarkers have improved the detection of clinically significant disease (Gleason Grade Group 2+), they fail to distinguish between high-grade cancer and genuinely lethal cancer, potentially leading to overtreatment and underscoring the need for next-generation tools that identify patients at true mortality risk.

David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.

Sacituzumab govitecan plus pembrolizumab may enable bladder preservation in MIBC.

A supplemental Biologics License Application has been submitted for nogapendekin alfa inbakicept-pmln (Anktiva) plus BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors.

The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.

AKY-1189 gains fast track designation in urothelial cancer.

CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Short-course enzalutamide in recurrent prostate cancer slashes PSA, but PSMA-PET tumor volume misleads, raising overtreatment concerns.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.

Phase 2 Daro-PET tests short-course darolutamide to boost PSMA PET signal in high-risk localized prostate cancer, guiding improved imaging interpretation.

PEACE-3 data show enzalutamide plus radium-223 extends survival and delays progression in bone-predominant mCRPC, with manageable added toxicity.

The phase 2 BRCAAway trial demonstrated that abiraterone acetate, prednisone, and olaparib significantly improves progression-free survival and overall survival compared with either agent used alone or sequentially in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 or ATM alterations.

Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 (Xofigo) will be presented at the 2026 ASCO GU Cancers Symposium.

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 therapy.

Highlights from the 2026 ASCO Genitourinary Cancer Symposium featuring key presentations in bladder, kidney, prostate, and rare cancers.

The rationale for KEYNOTE-B15 is to determine whether perioperative enfortumab Bedouin (Padcev) and pembrolizumab (Keytruda) can improve outcomes in patients with muscle-invasive bladder cancer compared with standard of care.

The 5-mg dose of oxybutynin reduced the frequency and severity of hot flashes in men with prostate cancer undergoing treatment with androgen-deprivation therapy compared with placebo.

New ASCO Living Guidelines on prostate cancer emphasize first-line therapies, bone protection, and the growing role of genetic testing.